Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Hannah Nealey

Nurse Practitioner, Psychiatric/Mental Health Fuquay Varina, NC Nurse Practitioner

NPI 1649793167 CMS profile 10645052

600 Stellata Dr, Fuquay Varina, NC 27526

Open in the dashboard

General payments

$75,287

738 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Hannah Nealey of Fuquay Varina, NC is reported in the CMS Open Payments database as having received $75,287 across 738 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Nurse Practitioner, Psychiatric/Mental Health profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $6,398 61
2024 General $4,609 124
2023 General $31,106 231
2022 General $20,640 157
2021 General $12,534 165

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Hannah Nealey
  • Nurse Practitioner, Psychiatric/Mental Health median
  • Middle half of Nurse Practitioner, Psychiatric/Mental Health
  • National median

In program year 2025, general payments to Hannah Nealey were reported at $6,398. Among 26,152 Nurse Practitioner, Psychiatric/Mental Health profiles paid that year, the median was $258 and the middle half received between $93 and $764.

Show as a table
Year Hannah Nealey Nurse Practitioner, Psychiatric/Mental Health median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $12,534 $166 $54–$482 $132
2022 $20,640 $195 $66–$559 $149
2023 $31,106 $233 $82–$673 $160
2024 $4,609 $236 $84–$688 $164
2025 $6,398 $258 $93–$764 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $66,236 288 payments
  2. Corium, Inc. $1,589 29 payments
  3. ITI, Inc. $1,054 89 payments
  4. Takeda Pharmaceuticals U.S.A., Inc. $623 40 payments
  5. Otsuka America Pharmaceutical, Inc. $561 35 payments
  6. Janssen Pharmaceuticals, Inc $542 25 payments
  7. Alkermes, Inc. $534 26 payments
  8. Neurocrine Biosciences, Inc. $456 26 payments
  9. Teva Pharmaceuticals USA, Inc. $441 25 payments
  10. Lundbeck LLC $434 23 payments
  11. Other $2,817 132 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $57,355 44 payments
  2. Food and Beverage $11,729 664 payments
  3. Travel and Lodging $6,018 28 payments
  4. Consulting Fee $173 1 payment
  5. Education $12 1 payment
Products named General payments · program years 2021–2025
  1. VRAYLAR Neuroscience $60,058 243 payments
  2. VRAYLAR Neuroscience $6,162 44 payments
  3. Azstarys $1,589 29 payments
  4. CAPLYTA $1,031 88 payments
  5. ARISTADA Cns $534 26 payments
  6. ARISTADA Cns $534 26 payments
  7. REXULTI $518 32 payments
  8. SPRAVATO $508 23 payments
  9. LYBALVI $475 23 payments
  10. TRINTELLIX $430 27 payments
  11. Other $6,177 315 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 6 drugs

Part D claims

112

Median for Nurse Practitioner: 389

Drug cost

$1,145

Median for Nurse Practitioner: $21,885

Branded share of claims

18.8%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Atomoxetine Hcl Generic 20 $557
Desvenlafaxine Succinate Er Desvenlafaxine Succinate Brand 21 $275
Quetiapine Fumarate Generic 15 $139
Alprazolam Generic 17 $79
Lorazepam Generic 16 $55
Lamotrigine Generic 23 $39

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 21 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VRAYLAR
$2,975 — —
CAPLYTA
$280 — —
INGREZZA
$167 — —
REXULTI
$126 — —
APLENZIN
$123 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 21 in the dashboard with a free account

Records

738 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record